Table 1 Patient and disease characteristics of the whole cohort and the five most frequent tumor entities
From: Sinonasal malignancies: histopathological entities, regional involvement and long-term outcome
Whole cohort (%) | Squamous cell carcinoma (%) | Adenocarcinoma (%) | Melanoma (%) | Adenoid cystic carcinoma (%) | Esthesio-neuroblastoma (%) | |
|---|---|---|---|---|---|---|
Total patients | 144 (100) | 74 (100) | 24 (100) | 18 (100) | 9 (100) | 7 (100) |
Male / female | 86 (59.7) / 58 (40.3) | 48 (64.9) / 26 (35.1) | 18 (75) / 6 (25) | 6 (33.3) / 12 (66.7) | 4 (44.4) / 5 (55.6) | 3 (42.9) / 4 (57.1) |
Median age; years (range) | 61.5 (10–93) | 59 (23–92) | 67.8 (29–86) | 74.9 (39–91) | 61.1 (40–93) | 63.6 (37–83) |
Tumor subsite | ||||||
Nasal cavity | 98 (68.1) | 54 (73.0) | 15 (62.5) | 14 (77.8) | 4 (44.4) | 3 (42.9) |
Paranasal sinuses | 37 (25.7) | 17 (23.0) | 7 (29.2) | 2 (11.1) | 4 (44.4) | 3 (42.9) |
Multiple subsites | 9 (6.3) | 3 (4.0) | 2 (8.4) | 2 (11.1) | 1 (11.1) | 1 (14.3) |
Clinical tumor classification | ||||||
T1 | 41 (28.5) | 28 (37.9) | 5 (20.1) | 2 (11.1) | 1 (11.1) | 3 (42.9) |
T2 | 22 (15.3) | 12 (16.2) | 2 (8.3) | 1 (5.6) | 2 (22.2) | 1 (14.3) |
T3 | 24 (16.7) | 7 (9.5) | 5 (20.1) | 8 (44.4) | 3 (33.3) | 0 |
T4a | 34 (23.6) | 18 (24.3) | 4 (16.7) | 5 (27.8) | 2 (22.2) | 3 (42.9) |
T4b | 23 (16) | 9 (12.2) | 8 (33.3) | 2 (11.1) | 1 (11.1) | 0 |
Clinical nodal classification | ||||||
N0 | 124 (86.1) | 64 (86.5) | 21 (87.5) | 15 (83.3) | 8 (88.9) | 7 (100) |
N1 | 8 (5.6) | 3 (4.1) | 0 | 3 (16.7) | 0 | 0 |
N2 | 12 (8.3) | 7 (9.5) | 3 (12.5) | 0 | 1 (11.1) | 0 |
Clinical distant metastasis classification | ||||||
M1 | 7 (4.9) | 3 (4) | 2 (8.3) | 1 (5.6) | 0 | 0 |